Adverse reactions reported in greater than or equal to 2% of QSYMIA-treated pediatric patients and more frequently than in the placebo group from a study in pediatric patients aged 12 years and older are shown in Table 2
13 , e035285 (2024)
Kidney function should be checked regularly, and any signs of dehydration or reduced urine output should be reported promptly
For patients evaluating current options, the practical question is whether a specific provider operates within the May 2026 compliance framework 503A pharmacy network, prescriber evaluation with documented clinical rationale, semaglutide base (not salt forms), LegitScript certification, and transparent operating practices
Exceptions to this rule are if supplements are stored in wet, hot, or humid areas and produce mold
The VA data here is exactly what we keep seeing in real-world clinical practice: when patients with obesity get access to GLP-1 therapy and stick with it, the downstream metabolic and cardiovascular improvements are substantial and consistent